Humacyte (NASDAQ:HUMA) Given “Buy” Rating at D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Humacyte (NASDAQ:HUMA) in a research report report published on Monday,Benzinga reports. D. Boral Capital currently has a $25.00 price target on the stock.

Several other brokerages also recently weighed in on HUMA. TD Cowen reiterated a “buy” rating and issued a $10.00 price target on shares of Humacyte in a report on Friday, October 18th. HC Wainwright reiterated a “buy” rating and issued a $15.00 price objective (up previously from $12.00) on shares of Humacyte in a research note on Friday, December 20th. Piper Sandler set a $6.00 target price on shares of Humacyte and gave the stock a “neutral” rating in a report on Friday, October 18th. BTIG Research reaffirmed a “buy” rating and issued a $10.00 price target on shares of Humacyte in a report on Friday, October 18th. Finally, Benchmark lifted their price objective on Humacyte from $15.00 to $17.00 and gave the company a “buy” rating in a research note on Monday, December 23rd. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $13.71.

Humacyte Stock Down 4.8 %

Humacyte stock opened at $4.39 on Monday. Humacyte has a fifty-two week low of $2.48 and a fifty-two week high of $9.97. The company has a market cap of $552.52 million, a PE ratio of -3.28 and a beta of 1.32. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.10 and a current ratio of 1.10. The business’s 50-day simple moving average is $4.66 and its two-hundred day simple moving average is $5.69.

Insider Transactions at Humacyte

In related news, Director Brady W. Dougan sold 427,459 shares of the company’s stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $4.34, for a total value of $1,855,172.06. Following the completion of the transaction, the director now owns 1,992,253 shares of the company’s stock, valued at approximately $8,646,378.02. This represents a 17.67 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Laura E. Niklason sold 261,369 shares of the firm’s stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $4.40, for a total value of $1,150,023.60. Following the completion of the sale, the chief executive officer now directly owns 1,730,884 shares in the company, valued at approximately $7,615,889.60. The trade was a 13.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 1,500,000 shares of company stock valued at $6,606,799 in the last ninety days. 11.20% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Humacyte

Several hedge funds and other institutional investors have recently added to or reduced their stakes in HUMA. Brookstone Capital Management acquired a new position in shares of Humacyte during the 4th quarter worth about $56,000. Concurrent Investment Advisors LLC purchased a new stake in Humacyte during the 3rd quarter worth approximately $75,000. Principal Financial Group Inc. acquired a new position in shares of Humacyte during the second quarter valued at approximately $83,000. FORA Capital LLC purchased a new position in shares of Humacyte in the third quarter valued at approximately $96,000. Finally, Profund Advisors LLC acquired a new stake in shares of Humacyte in the second quarter worth approximately $97,000. 44.71% of the stock is owned by hedge funds and other institutional investors.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.